US · Healthcare · Biotechnology
EPS came in at -0.44 against a street estimate of -0.53 — a beat of 17.0%.
Analysts rate Q32 Bio Inc a buy (1 buy, 2 hold, 0 sell out of 3) with an average price target of $41.00.
| Fund | Stake |
|---|---|
| Atlas Venture Life Science Advisors, LLC | 9.13% |
| Orbimed Advisors LLC | 7.57% |
| Opaleye Management Inc | 3.13% |
| Logos Global Management LP | 2.69% |
| Vanguard Capital Management, LLC | 1.03% |
| American Century Companies Inc | 0.92% |
| Mackenzie Investments | 0.83% |
| Sanofi | 0.82% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Q32 Bio Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.